Health News Releases

  • Today August 27
June 03, 2021 11:55
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon du
June 03, 2021 11:30
Benson Hill - Sustainable Food Technology Company Driving the Plant-Based Food Revolution - to Combine With Star Peak Corp II
Benson Hill, Inc. (the “Company” or “Benson Hill”), a food technology company unlocking the natural genetic diversity of plants, announced today that it will become publicly listed through a business
June 02, 2021 16:30
DentalMonitoring Continues to Disrupt the Orthodontic Market With AI-powered Solutions for Braces and Aligners of All Brands
The company that pioneered the field of virtual orthodontics and has been the market leader since 2014 is revolutionizing the industry once again with the only available AI-based virtual monitoring so
June 02, 2021 09:50
ZOLL and Global Healthcare SG Sign Exclusive Agreement for Distribution of Portable Targeted Temperature Management System in Asia Pacific
ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Global Healthcare SG, a developer of portable body cooling solutions, today anno
May 31, 2021 15:00
Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases
Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research. Waters™ SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that
May 31, 2021 14:10
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate
May 31, 2021 13:30
NEC’s AI Supports Doctors to Detect Neoplasia in Barrett’s Esophagus During Endoscopic Procedures
NEC Corporation (NEC; TOKYO: 6701) today announced the development of an AI technology for supporting doctors to detect neoplasia in Barrett’s esophagus during endoscopic procedures. This is the world
‘The NANUM Volunteer Corps’ of Siemens Korea are preparing daily necessities for around 230 househol
May 31, 2021 10:34
Siemens Korea Donates Daily Necessities for Needy Neighbors in the Local Community
A global powerhouse in electrical engineering and electronics Siemens Korea announced on May 31 that the company will carry out the ‘Delivery of Daily Necessities’ citizenship program with Seodaemun C
iTind is the newest addition to the portfolio of Olympus, a market leader in devices for BPH treatme
May 28, 2021 15:05
Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth
Olympus Corporation (”Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) announced today that it has finalized the acquisition of Israeli medical device company
May 27, 2021 15:30
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021
Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™
May 27, 2021 11:10
BIO KOREA 2021 International Convention to Unlock the Secret of Future Technologies
As one of the most important global bio-health conventions, BIO KOREA 2021 International Convention has garnered great attention from home and abroad. To facilitate the discussion on the future bio-he
May 25, 2021 15:40
Illumina and Microba Life Sciences Partner to Accelerate Microbiome Research
Illumina, Inc., the global leader in DNA sequencing and array-based technologies, announced today it united with leaders in precision gut microbiome science Microba Life Sciences to advance understand
May 24, 2021 16:30
Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, announced today the first presentation of interim data from a Phase 3 open-label study showing strong trends in efficacy and safety for investi
May 24, 2021 15:40
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitaliz
May 24, 2021 14:30
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dos
May 24, 2021 13:30
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with
May 24, 2021 11:50
CNPharm’s Game Changer COVID-19 Drug Introduced in World Class Academic Journal
Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article regarding the research results of CP-COV03, a Niclosamide-based ora
May 24, 2021 10:15
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted a New Drug Applic
May 24, 2021 10:10
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceu
May 21, 2021 11:50
Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced 40 abstracts, including seven oral presentations and seven poster discussions, from
May 20, 2021 16:00
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented d
May 20, 2021 15:00
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal grow
May 18, 2021 11:40
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate
May 18, 2021 10:30
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of PeriAnesthesia Nursing in which Drs. Mashasi Ishikawa and Atsuhiro Sakamoto at Nippon Medical School in Tokyo
Graph 1: CP-COV03’s SARS-CoV2 in-vivo efficacy study results
May 14, 2021 17:30
Hyundai Bioscience: Niclosamide-based CP-COV03, an Oral Antiviral Drug May Be a Problem Solver for COVID-19
Hyundai Bioscience (KOSDAQ 048410) announced that Dr. Jin-Ho Choi, a Chief Scientist of its major shareholding bio-tech company CNPharm and Chair Professor at Dankook University, presented the study t
25 per page50 per page75 per page100 per page